Physician profile
Mark J Burish
NPI 1154645653
$17,961.36
in general payments reported to CMS, 2019-2025
9 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2021: $134 · 2022: $33.87 · 2023: $1,130 · 2024: $6,381 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Honoraria: $5,503 · Travel and Lodging: $1,311 · Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,125.00 |
| Honoraria | $5,503.00 |
| Travel and Lodging | $1,310.65 |
| Food and Beverage | $697.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,003.19 | 2024-2025 | |
| H. Lundbeck A S | $4,373.28 | 2023-2024 | Vyepti |
| Lundbeck LLC | $2,260.00 | 2024 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $122.46 | 2021 | |
| Lilly USA, LLC | $91.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $65.67 | 2019 | |
| Abbvie INC. | $21.71 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.